Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

LEVI & KORSINSKY, LLP: TIMELINE OF ALLEGED MISREPRESENTATIONS IN VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION

prnewswire.com
VTGN The article discusses a class action lawsuit against Vistagen Therapeutics due to alleged misrepresentations. The primary reason for the lawsuit appears to be the company's disclosure of unexpected and statistically insignificant results in a Phase 3 trial, which contradicted prior positive observations.

LEVI & KORSINSKY, LLP: TIMELINE OF ALLEGED MISREPRESENTATIONS IN VISTAGEN THERAPEUTICS SECURITIES CLASS ACTION DEADLINE: March 16, 2026

NEW YORK, March 4, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP encourages investors who suffered losses in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) to contact the firm before the lead plaintiff deadline.

WHO IS AFFECTED: Those who purchased Vistagen securities between April 1, 2024 and December 16, 2025 may be entitled to recover damages.

Discuss your case with our attorneys or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.

APRIL 1, 2024 — CLASS PERIOD BEGINS

The Company announced enrollment of the first patient in its PALISADE-3 Phase 3 trial. Management stated that initiating the trial was "another major milestone" in the plan to develop and commercialize the drug candidate.

JUNE 11, 2024 — FISCAL YEAR RESULTS AND TRIAL ENHANCEMENTS

The Company published fiscal year 2024 results. Joshua Prince, the Chief Operating Officer, discussed "notable enhancements" and "operational changes" to optimize quality enrollment. The Company described improvements including in-person investigator meetings, rigorous training of sites, and enhanced oversight of study conduct.

NOVEMBER 3, 2025 — TRIAL COMPLETION ANNOUNCED

The Company announced completion of the Phase 3 public speaking challenge study. Management stated that the Company remained "encouraged" by the drug candidate's potential and that the same study design had been used with "certain protocol and operational enhancements."

DECEMBER 17, 2025 — CORRECTIVE DISCLOSURE

The Company disclosed that the Phase 3 study did not demonstrate a statistically significant improvement on the primary endpoint. Management characterized the results as "unexpected" and "inconsistent" with positive outcomes observed in prior studies.

WHAT YOU CAN DO

Check your eligibility to participate or contact Joseph E. Levi, Esq. at [email protected] | (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP

Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

SOURCE Levi & Korsinsky, LLP